Consortium partners


SynapCell SAS

SynapCell SAS

Further Information :

Organizational Activities

SynapCell is a private innovative Contract Research Organisation providing preclinical services in the field of CNS pathologies and particularly in the field of epilepsy. Incorporated in 2005 and based on a strong know-how in integrated electrophysiology, SynapCell has since developed and launched on the market innovative preclinical solutions based both upon predictive animal models of epilepsy, integrated electrophysiology and expert know-how. SynapCell’s solutions integrate chronic epilepsy animal models such as the Genetic Absence Epilepsy Rat from Strasbourg (GAERS (96) with an exclusive license from Inserm) and the MTLE mouse. These solutions allow the evaluation of the anti-epileptic effect of drug candidates by direct evaluation of the electrophysiological recordings of the discharges by EEG in vigil animals. Transgenic animals and the consequences of genetic modifications can also be explored with our solutions. SynapCell is a Young Innovative Company which devotes a part of its activity to the development of new predictive solutions in CNS pathologies. Located at the Biopolis seedbed center near the Health Campus of Grenoble, SynapCell benefits from laboratories and animal facilities dedicated to its activity. SynapCell has also developed collaboration with the Grenoble Institute of Neurosciences.

SynapCell will participate in the WP2 and will provide its experience in the model of epilepsy-mediated hippocampal degeneration, and particularly in the generation of MTLE mice and the study of epileptogenesis in different conditions with the use of integrated electrophysiology and EEG. More specifically, SynapCell will provide samples for high throughput assays and will offer its expertise in drug evaluation to test several NOX inhibitors.

Role in the Project

Key Personnel

Corinne Roucard, PhD, President-CEO: Corinne obtained her PhD in Immunology in 1996 at Paris VI University. She developed expertise in cell purification, cell culture on human primary cells, antigen presentation and immunological synapse. She worked in different European laboratories (London, Amsterdam, Paris and Grenoble). She became project leader of SynapCell in 2002 and CEO of the company in 2005. She is in charge of the general management of the company and supervises internal in vitro R&D projects based on hippocampal slice cultures.


Venceslas Duveau, PhD, Neuroscientist: Venceslas holds a PhD in Neuroscience and Neuropharmacology from the University Bordeaux 2 (FR). He was then appointed as post-doctoral researcher at the Institute of Pharmacology and Toxicology (University of Zurich, CH). Since January 2012, he is working as Neuroscientist, in charge of collaborative projects, in SynapCell. His fields of expertise are epilepsy and brain disorders.